Page last updated: 2024-11-06

pergolide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pergolide is a dopamine agonist that was originally developed for the treatment of Parkinson's disease. It works by stimulating dopamine receptors in the brain, which helps to improve motor function. However, pergolide was withdrawn from the market in 2007 due to concerns about its safety, particularly the risk of heart valve problems. It was synthesized in the 1970s as a derivative of ergot alkaloids. It was initially studied for its potential to treat Parkinson's disease, as it was found to have similar effects to dopamine. Research into pergolide focused on its mechanisms of action, its efficacy in treating Parkinson's disease, and its potential side effects. Despite its withdrawal, pergolide continues to be studied in the context of its mechanism of action and the development of new, safer dopamine agonists.'

Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID47811
CHEMBL ID1275
CHEMBL ID531
CHEBI ID63617
SCHEMBL ID26921
MeSH IDM0016279

Synonyms (112)

Synonym
BIDD:GT0177
AB00053740-13
BRD-K60770992-066-05-2
BRD-K60770992-001-01-8
(2r,4r,7r)-4-[(methylsulfanyl)methyl]-6-propyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene
gtpl48
DIVK1C_000442
KBIO1_000442
permax
(8beta)-8-[(methylthio)methyl]-6-propylergoline
(6ar,9r,10ar)-9-(methylthiomethyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline
ergoline, 8-((methylthio)methyl)-6-propyl-, (8beta)-
pergolidum [inn-latin]
pergolida [inn-spanish]
pergolide [inn:ban]
SPECTRUM_001647
BSPBIO_003156
IDI1_000442
PRESTWICK3_000295
BSPBIO_000230
BIOMOL-NT_000025
SPECTRUM5_001649
BPBIO1_000254
BPBIO1_001211
LOPAC0_000984
inchi=1/c19h26n2s/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20h,3,7-9,11-12h2,1-2h3/t13-,16-,18-/m1/s
66104-22-1
pergolide
C07425
DB01186
permax (tn)
NCGC00142538-01
NCGC00142538-03
KBIOSS_002127
KBIO3_002656
KBIO2_007263
KBIO2_004695
KBIO2_002127
KBIOGR_001409
PRESTWICK0_000295
SPBIO_002449
SPBIO_002099
SPECTRUM4_000835
SPECTRUM3_001588
SPECTRUM2_001970
PRESTWICK1_000295
NINDS_000442
PRESTWICK2_000295
NCGC00142538-02
(8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline
HMS2089C18
NCGC00017366-05
CHEMBL1275 ,
chebi:63617 ,
CHEMBL531 ,
D08339
pergolide (inn)
bdbm50017543
9-methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline, mesylate (pergolide)
cid_47811
[2-(1h-indol-4-yl)-ethyl]-methyl-amine
9-methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline
9-methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline(pergolide)
bdbm50028421
(6ar,9r,10ar)-9-methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline
9-methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinoline; compound with methanesulfonic acid
5-bromo-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid (10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxo-octahydro-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-amide
(6ar,9r,10ar)-9-methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinolin-7-ium
9-methylsulfanylmethyl-7-propyl-4,6,6a,7,8,9,10,10a-octahydro-indolo[4,3-fg]quinolin-7-ium(pergolide)
NCGC00017366-04
CCG-205064
SR-01000721840-8
sr-01000721840
NCGC00017366-03
NCGC00017366-06
NCGC00017366-02
pergolidum
pergolida
d-8beta-((methylthio)methyl)-6-propylergoline
ly 141b
unii-24mj822nz9
24mj822nz9 ,
pergolide [inn]
pergolide [mi]
pergolide [vandf]
pergolide [who-dd]
SCHEMBL26921
AB00053740_15
AB00053740_14
DTXSID2023438 ,
HY-13720
SBI-0050957.P003
NCGC00017366-10
BCP18331
Q415752
(6ar,9r,10ar)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline
8beta-[(methylthio)methyl]-6-propylergoline
YEHCICAEULNIGD-MZMPZRCHSA-N
P2200
BRD-K60770992-066-15-1
SDCCGSBI-0050957.P004
NCGC00017366-13
D92194
CS-0007749
(8beta)-8-((methylsulfanyl)methyl)-6-propylergoline
n04bc02
dtxcid203438
pergolida (inn-spanish)
pergolidum (inn-latin)
(2r,4r,7r)-4-[(methylsulfanyl)methyl]-6-propyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene
EN300-6482031
AKOS040744817

Research Excerpts

Overview

Pergolide is an ergot-derived dopamine agonist used in the treatment of Parkinson's disease and restless-legs syndrome. It has been associated with pleuropulmonary fibrosis and fibrotic cardiac valve disease. PerGolide appears to be an effective medical treatment for hyperprolactinemia and pituitary tumor.

ExcerptReferenceRelevance
"Pergolide is an ergot derived dopamine agonist that is widely used for the treatment of Parkinson's disease. "( Pergolide associated cardiac valvulopathy based on Ontario administrative data.
Duong-Hua, M; Lang, A; Marras, C; Rochon, P; Sykora, K; Zadikoff, C, 2008
)
3.23
"Pergolide is an ergot-derived dopamine agonist that has been associated with pleuropulmonary fibrosis and fibrotic cardiac valve disease."( Rounded atelectasis and respiratory compromise secondary to pergolide use.
Bloom, CI; Wilson, GE, 2009
)
1.32
"Pergolide is a dopamine agonist that improves Parkinson disease but is associated with dose-dependent sleepiness. "( Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy.
Comella, CL; Janko, K; Morrissey, M, 2005
)
2.05
"Pergolide is an ergot-derived dopamine agonist used in the treatment of Parkinson's disease and restless-legs syndrome."( [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
Bax, JJ; Jukema, JW; van Hilten, JJ; van Strater, AC, 2005
)
1.28
"Pergolide is a widely used antiparkinsonian dopamine agonist. "( [Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].
Bonnet, AM; Corvol, JC; Schüpbach, M, 2005
)
2.68
"Pergolide is an ergot derivative dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. "( Pergolide-associated valvular heart disease.
Kaplan, J; Waller, EA, 2006
)
3.22
"Pergolide appears to be an effective medical treatment for hyperprolactinemia and pituitary tumor and offers a possible alternative to bromocriptine and surgical treatment."( Effect of bromocriptine and pergolide on pituitary tumor size and serum prolactin.
Boyd, AE; Bryan, RN; Hamilton, DJ; Horowitz, BL; Sommers, CJ,
)
1.15
"Pergolide is an effective and safe ongoing medication for Parkinson's disease."( Pergolide in Parkinson's disease.
Glantz, R; Goetz, CG; Klawans, HL; Tanner, CM, 1983
)
2.43
"Pergolide mesylate is a synthetic ergoline with dopamine agonist properties. "( Pergolide mesylate: its effects on circulating anterior pituitary hormones in man.
Kaiser, DL; MacLeod, RM; Perryman, RL; Rogol, AD; Thorner, MO, 1981
)
3.15
"Pergolide mesylate is a potent dopamine agonist that is being evaluated clinically in Parkinson disease, hyperprolactinemia, and other diseases. "( Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
Clemens, JA; Fuller, RW; Hynes, MD, 1982
)
2.01
"Pergolide is an effective drug in patients with advanced Parkinson disease and reduces "on-off" phenomena."( Treatment of advanced Parkinson disease with pergolide.
Goldstein, M; Kleinberg, D; Kupersmith, M; Leibowitz, M; Lieberman, A; Neophytides, A; Pact, V, 1981
)
1.24
"Pergolide is a dopamine agonist with a potent stimulating effect on D2 and also on D1 receptors."( Pergolide mesylate in Parkinson's disease treatment.
Canesi, M; Mariani, CB; Pesenti, A; Pezzoli, G, 1995
)
2.46
"Pergolide is an ergotamine derivative with potent D1 and D2 receptor activity. "( Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration.
Barbier, P; Bravi, D; Colelli, A; Corsini, GU; Maggio, R, 1997
)
3.18
"Pergolide is a dopaminergic agonist used to treat Parkinson's disease but is associated with the development of retroperitoneal fibrosis (RPF). "( Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.
Lund, BC; Neiman, RF; Perry, PJ, 1999
)
1.99
"Pergolide is an ergot-derived dopamine agonist used in Parkinson's disease and, increasingly, in restless legs syndrome. "( Pleuropulmonary disease due to pergolide use for restless legs syndrome.
Danoff, SK; Flynn, JA; Grasso, ME; Terry, PB, 2001
)
2.04
"Pergolide is a potent, direct-acting dopamine agonist used in treating Parkinson's disease. "( Pergolide: a dopamine agonist at both D1 and D2 receptors.
Clemens, JA; Fuller, RW, 1991
)
3.17
"Pergolide mesylate is a dopamine agonist and, therefore, reduces prolactin secretion. "( Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. II: Perinatal and postnatal exposure.
Buelke-Sam, J; Cohen, IR; Owen, NV; Tizzano, JP,
)
1.83
"Pergolide is a synthetic ergoline derivative with highly potent long-acting PRL-lowering activity, allowing therapy of hyperprolactinemia with a once daily administration of the drug. "( A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Lamberts, SW; Quik, RF, 1991
)
1.99
"Pergolide is a potent dopamine agonist and is known to have anti-Parkinson properties. "( Treatment of Parkinson's disease with pergolide: a double-blind study.
Ahlskog, JE; Muenter, MD, 1988
)
1.99
"Pergolide is a safe and effective therapy for Parkinson's disease, even in patients with heart disease."( Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease.
Chhablani, R; Goetz, CG; Klawans, HL; Tanner, CM, 1985
)
2.43
"Pergolide is a useful drug in patients with advanced Parkinson's disease."( Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
Duvoisin, RC; Sage, JI, 1985
)
2.43

Effects

Pergolide has a long duration of action, thus reducing the wearing-off and end-of-dose phenomena frequently seen with long term levodopa therapy. This has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors.

Pergolide has a long duration of action, thus reducing the wearing-off and end-of-dose phenomena frequently seen with long term levodopa therapy. It has been used almost exclusively as an adjunct tolevodopa treatment.

ExcerptReferenceRelevance
"Pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia."( The pharmacokinetics of pergolide in Parkinson's disease.
Blin, O, 2003
)
1.35
"Pergolide has a long duration of action, thus reducing the wearing-off and end-of-dose phenomena frequently seen with long term levodopa therapy, suppressing fluctuations in levodopa response, and increasing total 'on' time."( Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.
Clissold, SP; Langtry, HD, 1990
)
2.44
"Pergolide, which has affinity for D2/D3 and D1-like receptors, reduced both startle and PPI, but only at the higher, nonspecific doses."( Dopamine D1 rather than D2 receptor agonists disrupt prepulse inhibition of startle in mice.
Geyer, MA; Lehmann-Masten, V; Ralph-Williams, RJ, 2003
)
1.04
"Pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia."( The pharmacokinetics of pergolide in Parkinson's disease.
Blin, O, 2003
)
1.35
"Pergolide has been used almost exclusively as an adjunct to levodopa treatment."( Pergolide mesylate in Parkinson's disease treatment.
Canesi, M; Mariani, CB; Pesenti, A; Pezzoli, G, 1995
)
2.46
"Pergolide has proven significantly superior to L-dopa plus peripheral decarboxylase inhibitor in short-term therapy of RLS/NMS. "( Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication.
Hünerjäger, H; Rüther, E; Staedt, J; Stoppe, G, 1998
)
3.19
"(5) Pergolide has not been compared with other dopamine agonists in double-blind trials."( Pergolide and Parkinson's disease: new preparation. No clear benefit.
, 2000
)
2.23
"Pergolide has a long duration of action, thus reducing the wearing-off and end-of-dose phenomena frequently seen with long term levodopa therapy, suppressing fluctuations in levodopa response, and increasing total 'on' time."( Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.
Clissold, SP; Langtry, HD, 1990
)
2.44

Actions

Pergolide can produce a fibrotic process in heart valves, resulting in valve insufficiency in up to 25% of cases. The drug is known to cause pericardial and pleural effusion and generalized oedema.

ExcerptReferenceRelevance
"Pergolide is known to cause pericardial and pleural effusion, and generalized oedema. "( Reversible Hypotony and Choroidal Effusion Following the Use of Pergolide for Parkinson's Disease.
Andreatta, W; Shah, P, 2015
)
2.1
"Pergolide can produce a fibrotic process in heart valves, resulting in valve insufficiency in up to 25% of cases."( Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease.
Apostolakis, EE; Baikoussis, NG; Fokaeas, E; Karanikolas, M; Koniari, I; Prokakis, C; Tselikos, D, 2009
)
1.29
"Pergolide appears to lower blood pressure by a novel mechanism of action and may offer an additional therapeutic approach for the treatment of hypertension."( Central and peripheral dopaminergic mechanisms in the cardiovascular actions of pergolide in neurogenic hypertensive dogs.
Barrett, RJ; Lokhandwala, MF, 1983
)
1.21
"Pergolide continued to suppress body weight with no indications of tolerance."( Behavioral effects of pergolide mesylate on food intake and body weight.
Garbin, CP; Greene, SB; Hollingsworth, EM; Mathews, D, 1985
)
1.31

Treatment

Treatment with pergolide mesylate plus thyroidectomy reduced both serum prolactin and growth hormone in all of 14 rats, caused regression of ten of the 14 tumors (71%), while two became static, and two continued to grow. Treatment was not associated with any specific target organ toxicity.

ExcerptReferenceRelevance
"Pergolide treatment was initiated after Day 0 collections."( Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Adams, AA; Barker, VD; Bush, HM; Campana-Emard, AG; Grubbs, ST; Hart, KA; Loynachan, AT; Miller, AB, 2021
)
1.58
"Pergolide treated horses lost weight (P = 0.02) and improved fasting insulin (P = 0.02), while placebo treated horses gained weight and rump fat thickness (P = 0.02)."( Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy.
Banse, HE; Chelikani, PK; McFarlane, D; Whitehead, AE, 2021
)
1.59
"Pergolide treatment started with a dose escalation period of 12 weeks followed by a 12-week continuation period."( High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arnold, G; Gasser, T; Hundemer, HP; Kupsch, A; Lipp, A; Schwarz, J; Storch, A,
)
1.21
"Pergolide/ondansetron treatment, but not pergolide alone, consistently reversed both the behavioral sensitization and the associated changes in the NMDA and AMPA receptor subunits."( Reversal of cocaine-induced behavioral sensitization and associated phosphorylation of the NR2B and GluR1 subunits of the NMDA and AMPA receptors.
Davidson, C; Ellinwood, EH; Lazarus, C; Lee, TH; Wetsel, WC; Zhang, X, 2007
)
1.06
"Pergolide treatment was not associated with any specific target organ toxicity.(ABSTRACT TRUNCATED AT 250 WORDS)"( Preclinical toxicology studies with the new dopamine agonist pergolide. Acute, subchronic, and chronic evaluations.
Adams, ER; Carlson, KH; Francis, PC; Owen, NV, 1994
)
1.25
"Pergolide treatment significantly improved clinical symptoms and sleep efficiency, and reduced periodic limb movements of sleep in patients with RLS."( Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome.
Allen, RP; Earley, CJ; Yaffee, JB, 1998
)
1.99
"Pergolide-treated patients experienced a significantly greater improvement than placebo-treated patients (p < 0.001) in UPDRS (overall, part II, and part III) score, Schwab & England score, and Clinical Global Impression improvement score."( Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group.
Barone, P; Bermejo-Pareja, F; Bravi, D; Kulisevsky, J; Malagù, S; Marconi, R; Rost, N; Weiser, R, 1999
)
2.47
"Pergolide treatment resulted in only minor alterations in striatal 3H-spiperone binding and no change in dendritic arborizations of either DA substantia nigra neurons or medium spiny striatal neurons."( Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats.
Clemens, JA; Felten, DL; Felten, SY; Fuller, RW; Romano, TD; Smalstig, EB; Wong, DT,
)
1.2
"Pergolide treatment also did not decrease thromboxane B2, prostaglandin E2 or leukotriene B4 production, ruling out direct effects on arachnoid acid inflammatory mediators."( Anti-inflammatory activity of pergolide, a dopamine receptor agonist.
Bendele, AM; Benslay, DN; Bryant, HU; Spaethe, SM, 1991
)
1.29
"Treatment with pergolide did not affect the ventricular function nor induce valvular disease."( Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
Fisch, J; Gehlen, H; Merle, R; Trachsel, DS, 2021
)
1.24
"Treatment with pergolide specifically affected genes involved in homeostasis, which was corroborated by the activation of the master regulator of cell energy homeostasis, AMPK-α, as well as decreased levels of metabolism-related miR-107."( Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling.
Donis, N; Dulgheru, R; Fillet, M; Hego, A; Hulin, A; Lancellotti, P; Maréchal, P; Nchimi, A; Nguyen, ML; Oury, C; Tridetti, J, 2020
)
1.22
"Treatment of pergolide started when the patient was 49."( [Pergolide-induced pleural effusion in a patient with juvenile parkinsonism].
Kuwabara, T, 2002
)
1.58
"Pretreatment with pergolide significantly reduced this habituation impairment."( [Effects of D1 and D2 dopamine receptor agonists and antagonists on cerebral ischemia/reperfusion injury].
Lü, JN; Xu, T; Zeng, YM; Zong, XM, 2003
)
0.64
"The treatment with pergolide in these cases might be more beneficial than with short-acting PDE-5 inhibitor sildenafile."( The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial.
Bares, M; Kanovský, P; Pohanka, M; Pulkrábek, J; Rektor, I, 2005
)
0.86
"Treatment with Pergolide alone was then started; and sleep monitoring showed suppression of REM rebound, REM only appearing when the dose of the drug was reduced."( Suppression of REM rebound by Pergolide.
Askenasy, JJ; Yahr, MD, 1984
)
0.9
"Treatment with pergolide mesylate plus thyroidectomy reduced both serum prolactin and growth hormone in all of 14 rats, caused regression of ten of the 14 tumors (71%), while two became static, and two continued to grow."( Influence of thyroidectomy and prolactin suppression on the growth of N-nitrosomethylurea-induced rat mammary carcinomas.
Mountjoy, KG; Rose, DP, 1983
)
0.61
"Treatment with pergolide was compared with bromocriptine in 25 patients, all of whom were also receiving levodopa and in all of whom the response to levodopa had diminished. "( Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
Goldstein, M; Goodgold, A; Gopinathan, G; Leibowitz, M; Lieberman, AN; Neophytides, A; Pact, V; Walker, R, 1983
)
0.93
"Treatment with pergolide often allows substantial reductions in concomitant levodopa dosage, and occasionally levodopa can be completely replaced by pergolide therapy in short term use."( Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.
Clissold, SP; Langtry, HD, 1990
)
2.06

Toxicity

No adverse effects of pergolide treatment were found in the 1 mg/kg/day group. A high incidence of adverse events was noted especially at the initiation of therapy.

ExcerptReferenceRelevance
" No adverse effects of pergolide treatment were found in the 1 mg/kg/day group."( Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. I: Gestational exposure.
Buelke-Sam, J; Byrd, RA; Johnson, JA; Owen, NV; Tizzano, JP,
)
0.7
" There were no adverse effects on growth, development or reproductive performance in the F1 treatment-derived generation."( Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. II: Perinatal and postnatal exposure.
Buelke-Sam, J; Cohen, IR; Owen, NV; Tizzano, JP,
)
0.39
" A high incidence of adverse events was noted especially at the initiation of therapy with both compounds: nausea, dizziness, vomiting, asthenia, headache, and decrease in blood pressure occurred at a similar incidence and extent during the use of pergolide and bromocriptine."( A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Lamberts, SW; Quik, RF, 1991
)
0.73
"in these 24-week studies comprising a total of 157 hyperprolactinemic patients, a once daily administration of pergolide was shown to be as safe and effective as the two to four times daily ingestion of bromocriptine."( A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia.
Lamberts, SW; Quik, RF, 1991
)
0.76
" Pergolide is a safe and effective therapy for Parkinson's disease, even in patients with heart disease."( Pergolide mesylate: lack of cardiac toxicity in patients with cardiac disease.
Chhablani, R; Goetz, CG; Klawans, HL; Tanner, CM, 1985
)
2.62
"In this preliminary report from a placebo-controlled, double-blind, dose-response study on the use of pergolide mesylate for cocaine dependence in outpatients 8 out of 235 subjects noted adverse events requiring breaking of the blind."( Pergolide mesylate. Adverse events occurring in the treatment of cocaine dependence.
Cochrane, CE; Kajdasz, DK; Malcolm, R; Moore, JW, 1997
)
1.95
" Adverse events were studied for 6 weeks."( Quick titration of pergolide in cotreatment with domperidone is safe and effective.
De Vreede, PL; Herings, RM; Hovestadt, A; Jansen, PA; Samson, MM; Schuurmans-Daemen, LM; Van Laar, T; Verhaar, HJ,
)
0.46
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Adverse events, all of which were mild, occurred in 29."( Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching.
Abe, T; Hamada, T; Kashihara, K; Kawamura, J; Kowa, H; Nogawa, S; Ogino, Y; Tachibana, H; Takahashi, H,
)
0.13

Pharmacokinetics

Pergolide has a long half-life of about 21 h. This has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia. Twice-daily dosing may be more appropriate than once- daily dosing.

ExcerptReferenceRelevance
" Pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia."( The pharmacokinetics of pergolide in Parkinson's disease.
Blin, O, 2003
)
1.54
" Using models for disease progression and pharmacodynamic models for drug effects we have characterized the changes in UPDRS over time to determine the influence of the various drug treatments."( Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.
Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I, 2006
)
0.33
"This review describes the pharmacologic and pharmacokinetic properties of selected DAs and relates these characteristics to clinical outcomes, with an emphasis on adverse events."( A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
Burger, E; Härtter, S; Kvernmo, T, 2006
)
0.33
" The most common treatment for PPID is pergolide, a dopamine agonist; however, there are no pharmacokinetic data about the use of this drug in horses."( Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.
Apley, M; Beard, L; Coetzee, J; Gehring, R; Havel, J; Wright, A, 2010
)
0.9
" One of the barriers associated with pergolide determinations in plasma for pharmacokinetic applications has been the technically demanding requirement for sensitivity."( Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications.
Davies, NW; Edwards, S; Hughes, KJ; Jacobson, GA; Pirie, A; Rendle, DI, 2014
)
1.02
" Pergolide concentrations in plasma were determined by means of high-performance liquid chromatography-tandem mass spectrometry, and pharmacokinetic parameters were determined on the basis of noncompartmental methods."( Pharmacokinetics of pergolide after intravenous administration to horses.
Doran, GS; Edwards, SH; Hughes, KJ; Rendle, DI, 2015
)
1.65
"With an elimination half-life of approximately 6 hours, twice-daily dosing may be more appropriate than once-daily dosing to reduce peak-trough fluctuation in pergolide concentrations."( Pharmacokinetics of pergolide after intravenous administration to horses.
Doran, GS; Edwards, SH; Hughes, KJ; Rendle, DI, 2015
)
0.94
"Published information on the pharmacokinetic and pharmacodynamic properties of pergolide is limited."( Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Doran, G; Edwards, S; Ireland, J; Rendle, DI, 2019
)
1.01

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Pergolide is one of the most well-tested and widely used dopamine agonists for the treatment of Parkinson's disease. With an elimination half-life of approximately 6 hours, twice- daily dosing may be more appropriate than once-daily dosing to reduce peak-trough fluctuation.

ExcerptRelevanceReference
" Dose-related hyperactivity, chewing and squinting that were consistent with dopaminergic stimulation occurred following dosing in the 20 and 60 mg/kg/day groups; F0 body weights and food consumption were reduced during the initial phase of treatment in the 60 mg/kg/day group."( Developmental toxicity of the dopamine agonist pergolide mesylate in CD-1 mice. I: Gestational exposure.
Buelke-Sam, J; Byrd, RA; Johnson, JA; Owen, NV; Tizzano, JP,
)
0.39
" The dose-response curve for APO-induced yawning was not changed by alpha MPT (200 mg/kg), while the suppression of exploration induced by APO, but not by pergolide, was enhanced by pretreatment with alpha MPT."( Yawning and suppression of exploration induced by dopamine agonists: no relation to extracellular striatal levels of dopamine.
Ståhle, L; Ungerstedt, U, 1990
)
0.48
" Pergolide in doses of 2 mg per day considerably and durably improved the parkinsonian symptoms and enabled the patients to reduce L-dopa dosage by about 50%."( [Clinical study of pergolide in Parkinson's disease].
Delwaide, PJ; Gonce, M, 1985
)
1.51
") and shifted to the right the dose-response curve for agonist-induced hypothermia."( SCH 23390 antagonizes apomorphine- and ergot-induced hypothermia.
Carboni, E; Deidda, S; Di Chiara, G; Longoni, R, 1986
)
0.27
" However, large differences were found when comparing apomorphine and pergolide dose-response curves as well as the patterns of rotational behaviour the compounds elicited."( Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites.
Herrera-Marschitz, M; Ungerstedt, U, 1984
)
0.79
"It was proposed that apomorphine and the ergot derivative pergolide induce rotation in 6-hydroxy-dopamine (6-OHDA)-denervated rats by different receptor mechanisms, since these dopamine agonists induce different patterns of rotational behaviour, have different dose-response curves and are differently inhibited by neuroleptics acting on D1 or D2 type receptors."( Evidence that striatal efferents relate to different dopamine receptors.
Herrera-Marschitz, M; Ungerstedt, U, 1984
)
0.51
" To avoid side effects, the starting dosage should be low (1."( Dopamine agonists in the treatment of Parkinson's disease.
Koller, WC; Pahwa, R,
)
0.13
" Pergolide dosage was gradually built up until an optimal dosage was achieved."( An open label trial of pergolide in Thai patients with Parkinson's disease.
Devahasatin, V; Poungvarin, N; Prayoonwiwat, N; Viriyavejakul, A, 1996
)
1.51
"In this preliminary report from a placebo-controlled, double-blind, dose-response study on the use of pergolide mesylate for cocaine dependence in outpatients 8 out of 235 subjects noted adverse events requiring breaking of the blind."( Pergolide mesylate. Adverse events occurring in the treatment of cocaine dependence.
Cochrane, CE; Kajdasz, DK; Malcolm, R; Moore, JW, 1997
)
1.95
" After a 6-week open-label, fixed-flexible dosing schedule, response to pergolide on standard GTS severity outcome measures was assessed."( Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide.
Jackson, C; Lipinski, JF; Sallee, FR; Sethuraman, G, 1997
)
0.75
" Hallucinosis was not associated with age at onset of idiopathic Parkinson's disease or dosage of dopaminergic medication."( Hallucinosis in idiopathic Parkinson's disease.
Graham, JM; Grünewald, RA; Sagar, HJ, 1997
)
0.3
" Consumption was expressed in defined daily dosage (DDD) and the costs in euros."( [The evolution of use of anti-Parkinson drugs in Spain].
Castel, JM; Montané, E; Vallano Ferraz, A,
)
0.13
" In this group of patients with most serious motor disability, it has been possible to improve dyskinesia and fluctuations with a relatively important dosage of pergolide and without increase of levodopa dosage."( [Pergolide: a useful agonist for the treatment of Parkinson disease].
Bonnet, AM; Houeto, JL, 2002
)
1.42
" Pergolide had been used since 1990 at the maximum dosage of 2,250 micrograms/day."( [Pergolide-induced pleural effusion in a patient with juvenile parkinsonism].
Kuwabara, T, 2002
)
2.14
" The main risk factor associated with pathologic daytime sleep latency was high levodopa dosage equivalents (>867."( Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Lang, AE; Razmy, A; Shapiro, CM, 2004
)
0.32
" Physicians concerned with daytime hypersomnolence in PD patients treated with dopamine agonists and receiving high levodopa dosage equivalents should consider polysomnographic monitoring for impaired daytime sleep latency."( Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.
Lang, AE; Razmy, A; Shapiro, CM, 2004
)
0.32
"5-15 mg/day adjunctive to l-dopa were selected to replace bromocriptine with pergolide of the equivalent dosage approved in Japan."( Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients.
Araki, I; Kuno, S; Mizuta, E; Yamasaki, S, 2004
)
0.94
"Pergolide is one of the most well-tested and widely used dopamine agonists for the treatment of Parkinson's disease; however, there is worrying evidence that sub-therapeutic dosing of pergolide is widespread in clinical practice."( Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease.
Hattori, N, 2003
)
2.08
" Tolcapone produced a greater reduction in levodopa dosage than bromocriptine."( Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Clarke, CE; Deane, KH; Spieker, S, 2004
)
0.32
"For the purpose of determining the optimal dose, pergolide was administered to patients with Parkinson's disease using a dose-escalation protocol up to the maximum dosage permissible in Japan."( [Optimum dosage of pergolide in patients with Parkinson's disease].
Neshige, R, 2005
)
0.91
" Associations with dosage and years of treatment also were examined."( Valvular heart disease in patients taking pergolide.
Heckman, MG; Kaplan, J; Waller, EA, 2005
)
0.59
" There was marginal evidence of an association between a higher daily dosage of pergolide and moderate to severe AR (P = ."( Valvular heart disease in patients taking pergolide.
Heckman, MG; Kaplan, J; Waller, EA, 2005
)
0.82
" However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication."( Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
Chung, EJ; Kim, JY; Lee, WY; Park, SW, 2006
)
0.33
" Oral dosage with 150 microg pergolide did not have any effect on his RLS symptoms."( [Effect of high dose pergolide mesilate on restless legs syndrome associated with Parkinson disease].
Imamura, A; Obata, T; Tanaka, M; Tsuboi, Y; Yamada, T, 2007
)
0.95
" The patient has been suffered from Parkinson's disease for 12 years and prescribed levodopa, selegiline, and small dosage of pergolide (200 microg/day)."( [Low dose pergolide induced systemic edema and pleural effusion in a patient with Parkinson's disease].
Chihara, N; Hayakawa, M; Nakase, H; Shiio, Y; Yoshimura, M, 2008
)
0.95
" However, the mean pergolide dosage in our study was lower than in previous studies."( Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both.
Aydemir, T; Bader, H; Cetin, S; Kizkin, S; Meral, H; Ozben, B; Ozben, S; Ozer, F; Ozturk, O; Tiras, R, 2009
)
0.91
" To make definitive dosing recommendations to clinicians, more studies will be needed to investigate the relationship between plasma pergolide concentrations and clinical outcomes, as well as the effect of gender, age, and concomitant disease on the absorption and disposition of this drug."( Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.
Apley, M; Beard, L; Coetzee, J; Gehring, R; Havel, J; Wright, A, 2010
)
0.84
" Neither disease severity nor L-dopa dosage correlated with plasma AVP levels."( Increased plasma arginine vasopressin levels in dopamine agonist-treated Parkinson's disease patients.
Arai, M, 2011
)
0.37
" Pergolide was withdrawn from the US market in 2007 because of the risk of valvular heart disease, while the European Medicines Agency (EMA) required a reduction in the maximum daily dosage of cabergoline and pergolide from 6 mg/day to 3 mg/day in 2008."( The impact in Japan of regulatory action on prescribing of dopamine receptor agonists: analysis of a claims database between 2005 and 2008.
Kubota, K; Ooba, N; Yamaguchi, T, 2011
)
1.28
" After their dopaminergic treatment had been changed to a less pulsatile form of administration (ie, the use of dopamine agonist alone in the first patient and an increase in the dosage of dopamine agonist with a low dose of levodopa in the second), these abnormal movements totally disappeared in the first patient and were greatly improved in the second."( Continuous buccolingual masticatory dyskinesia in Parkinson's disease.
Damier, P; Derkinderen, P; Giumelli, B; Meyniel, C, 2012
)
0.38
" The assay was applied to samples from a horse dosed with 10mg pergolide (as the mesylate salt) by nasogastric intubation."( Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications.
Davies, NW; Edwards, S; Hughes, KJ; Jacobson, GA; Pirie, A; Rendle, DI, 2014
)
0.98
" In early PD, this may avoid dose escalation or allow a reduction in dopamine agonist dosage without a loss of efficacy and prevent dopaminergic side-effects from becoming treatment limiting."( The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Okita, E; Soshiroda, K; Uchida, S, 2015
)
0.42
"With an elimination half-life of approximately 6 hours, twice-daily dosing may be more appropriate than once-daily dosing to reduce peak-trough fluctuation in pergolide concentrations."( Pharmacokinetics of pergolide after intravenous administration to horses.
Doran, GS; Edwards, SH; Hughes, KJ; Rendle, DI, 2015
)
0.94
" To reduce the level of fluctuation of ACTH, twice-daily dosing of pergolide may be more appropriate."( Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Doran, G; Edwards, S; Ireland, J; Rendle, DI, 2019
)
1.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antiparkinson drugA drug used in the treatment of Parkinson's disease.
dopamine agonistA drug that binds to and activates dopamine receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
diamineAny polyamine that contains two amino groups.
organic heterotetracyclic compound
methyl sulfideAny aliphatic sulfide in which at least one of the organyl groups attached to the sulfur is a methyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (68)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dopamine D1 receptorHomo sapiens (human)Potency0.01840.00521.30228.1995AID624455
phosphopantetheinyl transferaseBacillus subtilisPotency79.43280.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency5.01190.35487.935539.8107AID624146
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency37.68580.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency0.38410.02245.944922.3872AID488982; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency12.58930.01789.637444.6684AID588834
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency12.58930.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency12.58931.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.37900.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.19900.00000.887110.0000AID625218
5-hydroxytryptamine receptor 1AHomo sapiens (human)Ki0.00400.00010.532610.0000AID4447
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.38500.00040.629810.0000AID203936
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.26400.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.09900.00010.807410.0000AID625201
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.20000.00002.015110.0000AID625249
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.11100.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki0.02850.00000.651810.0000AID1154610; AID625253; AID63227; AID63977
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.38500.00040.908610.0000AID203936
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.06400.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.02900.00020.725710.0000AID625202
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)1.41000.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.20500.00030.483410.0000AID625203
DRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00030.50267.7625AID62729; AID62862
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00030.39075.4000AID62729; AID62862
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.20000.00031.38338.4000AID203936; AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.00850.00010.739610.0000AID625190
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.04100.00031.09147.7625AID36797
D(2) dopamine receptorBos taurus (cattle)IC50 (µMol)0.06030.00100.79948.0000AID62437; AID62438
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)0.67900.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki1.45970.00010.836310.0000AID625252; AID63040
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.04100.00031.09147.7625AID36797
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.04100.00031.06917.7625AID36797
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)1.51300.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.74400.00000.360910.0000AID625200
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00030.35635.4000AID62729; AID62862
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.01400.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.00390.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.37900.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.19900.00010.954910.0000AID625218
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.20000.00051.48357.8000AID203936; AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.00850.00031.29679.2440AID625190
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)IC50 (µMol)0.38500.00311.73607.8000AID203936
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00030.38715.4000AID62729; AID62862
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)IC50 (µMol)0.38500.00501.79627.8000AID203936
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.38500.00040.615610.0000AID203936
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)IC50 (µMol)0.38500.00501.50894.6000AID203936
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)IC50 (µMol)0.38500.00501.42824.6000AID203936
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)IC50 (µMol)0.38500.00501.35984.6000AID203936
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)IC50 (µMol)0.38500.00501.35984.6000AID203936
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)0.00540.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.00220.00000.602010.0000AID239943; AID625254; AID65774
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)IC50 (µMol)0.38500.00021.13514.6000AID203936
Alpha-synucleinHomo sapiens (human)IC50 (µMol)7.90000.19003.82049.8000AID1695731
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.07600.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.04900.00030.769310.0000AID625217
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)0.03900.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.01800.00020.522910.0000AID625221
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00310.00010.54948.4000AID62729; AID62862
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.00100.00000.437510.0000AID65415
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)0.12020.00091.901410.0000AID576612
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)IC50 (µMol)0.38500.00501.35524.6000AID203936
DBos taurus (cattle)IC50 (µMol)0.06030.00100.47208.0000AID62437; AID62438
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.38500.00030.70285.3660AID203936
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)IC50 (µMol)0.38500.00041.17424.6000AID203936
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
mu-type opioid receptor isoform MOR-1Homo sapiens (human)EC50 (µMol)92.47000.13203.30049.5690AID720642
5-hydroxytryptamine receptor 2AMus musculus (house mouse)EC50 (µMol)0.95900.00381.36218.3930AID720643
D(2) dopamine receptorHomo sapiens (human)EC50 (µMol)0.00040.00000.18743.9000AID1340444
5-hydroxytryptamine receptor 2AHomo sapiens (human)EC50 (µMol)0.00890.00000.22763.4750AID1340445
5-hydroxytryptamine receptor 2CHomo sapiens (human)EC50 (µMol)0.21880.00010.10082.4500AID1340446
D(2) dopamine receptorRattus norvegicus (Norway rat)Kd0.02980.00030.81836.7000AID64790; AID64917; AID64919; AID64925
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (357)

Processvia Protein(s)Taxonomy
behavioral fear response5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
gamma-aminobutyric acid signaling pathway5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of serotonin secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of vasoconstriction5-hydroxytryptamine receptor 1AHomo sapiens (human)
exploration behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of dopamine metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin metabolic process5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of hormone secretion5-hydroxytryptamine receptor 1AHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1AHomo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
synaptic transmission, dopaminergicDBos taurus (cattle)
vasodilationDBos taurus (cattle)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (75)

Processvia Protein(s)Taxonomy
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
receptor-receptor interaction5-hydroxytryptamine receptor 1AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 1AHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (64)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1AHomo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endoplasmic reticulum membraneDBos taurus (cattle)
dendritic spineDBos taurus (cattle)
ciliary membraneDBos taurus (cattle)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (172)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID62430Dopamine receptor binding affinity by displacing the radioligand [3H]spiroperidol from dopamine receptor.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID193327Ability to lower the serum prolactin levels in comparison with that of pergolide expressed as percent inhibition change at ip dose of 0.05 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID188340Ability to lower the serum prolactin levels in comparison with that of pergolide was determined for the drug-treated rats at ip dose of 0.005 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID33113In vitro affinity for alpha adrenergic receptor by displacement of 3[H]clonidine in calf cerebral cortex1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID47766Compound was tested for percentage decrease in heart rate at 30 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID395326Fraction unbound in rat brain2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID189807Effect on serum corticosterone level in whole rat brain when 10 mg/kg was administered intraperitoneally1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID188333Ability to lower the serum prolactin levels in comparison with that of pergolide was determined for the control rats at ip dose of 0.005 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID218777Inhibition of [3H]dopamine binding to dopamine receptor of rat corpus striatum1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline.
AID239943Inhibition constant against [3H]-spiperone binding to human Dopamine receptor D3 expressed in CHO cells2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
CoMFA and CoMSIA investigations revealing novel insights into the binding modes of dopamine D3 receptor agonists.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID196131Ability to induce contralateral rotational behavior in unilateral 6-hydroxydopamine nigrostriatal-lesioned rats and percent of rats turning was determined at intraperitoneal dosage of 1.0 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID62310Dopamine receptor binding affinity by displacing the radioligand [3H]-dopamine from dopamine receptor.1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID193325Ability to lower the serum prolactin levels in comparison with that of pergolide expressed as percent inhibition change at ip dose of 0.005 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID48530Compound was tested for neuronal inhibition of postganglionic cardio accelerator nerve stimulation in anaesthetized cat at 2 Hz frequency at 10 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID64919In vitro affinity at mutant D2 receptor (S197A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID62862In vitro affinity for dopamine receptor by displacement of [3H]- apomorphine in rat striatal membranes1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity.
AID1695731Inhibition of alpha-synuclein fibril formation (unknown origin) incubated for 6 days by thioflavin S based fluorescence assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation.
AID189808Reduction of serum prolactin concentration in rats, 5 mg/Kg administered intraperitoneally1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID162618Evaluated for the prolactin inhibition at the dose 50 ug/kg administered intraperitoneally1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Conversion of ergolines to hexahydro- and octahydrobenzo[f]quinolines (depyrroloergolines).
AID227608Intrinsic activity against dopamine D 2 receptor1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID191323Evaluation for contralateral turning in 6-hydroxy-dopamine-lesioned rats administered intraperitoneally at the dose 1 mg/kg total turnings1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID177696In vivo measure of dopaminergic activity by the induction of contralateral turning behavior in 6-hydroxydopamine (6-OHDA) lesioned rats, ip1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Synthesis of (7R)-7H-indolo[3,4-gh][1,4]benzoxazines, a new class of D-heteroergolines with dopamine agonist activity.
AID188342Ability to lower the serum prolactin levels in comparison with that of pergolide was determined for the drug-treated rats at ip dose of 0.05 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID48521Compound was tested for percentage increase in mean arterial blood pressure at 30 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID47767Compound was tested for percentage decrease in heart rate at 3 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID48533Compound was tested for neuronal inhibition of postganglionic cardio accelerator nerve stimulation in anaesthetized cat at 2 Hz frequency at 3 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID203935In vitro inhibitory activity against serotonin receptor from rat frontal cortex using [3H]spiperone as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID36919In vitro inhibitory activity against alpha-2 adrenergic receptor from rat brain minus cerebellum using [3H]clonidine as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID4447Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
AID36861In vitro inhibitory activity against alpha-1 adrenergic receptor from whole rat brain using [3H]WB-4101 as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID190397Evaluated for the Average turns per first 15 minutes after administration of 1 mg/kg intraperitoneally1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Conversion of ergolines to hexahydro- and octahydrobenzo[f]quinolines (depyrroloergolines).
AID62437In vitro inhibitory activity against dopamine receptor from calf caudate using [3H]dopamine as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID182951In vivo inhibitory activity against ovum implantation in female rat after subcutaneous administration1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID183408Inhibition of serum prolactin concentration in rats when 5 mg/Kg was administered intraperitoneally1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID64455Inhibitory activity against Dopamine receptor D2 in rat corpus striatum using [3H]Apomorphine as radioligand1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
AID48543Compound was tested for inhibitory effect reversed by haloperidol (100 ug/kg) at 3 mg/kg in anaesthetized cat; yes1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID189493Evaluated for the rat turning after administration of 1 mg/kg intraperitoneally1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Conversion of ergolines to hexahydro- and octahydrobenzo[f]quinolines (depyrroloergolines).
AID174605Evaluation for contralateral turning in 6-hydroxy-dopamine-lesioned rats administered intraperitoneally at the dose 1 mg/kg duration1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID1154610Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID48532Compound was tested for neuronal inhibition of postganglionic cardio accelerator nerve stimulation in anaesthetized cat at 2 Hz frequency at 30 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID64925In vitro affinity at wild type Dopamine receptor D2 on C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID63977Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID189802Effect on dopamine concentration in whole rat brain when 10 mg/Kg was administered intraperitoneally1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
AID47772Compound was tested for percentage decrease in mean arterial blood pressure at 30 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID64790In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID178347Determination of ED50 for induction of turning contralateral in 6-hydroxydopamine (6-OHDA) lesioned rats by ip administration1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists.
AID162619Evaluated for the prolactin inhibition at the dose 50 ug/kg administered intraperitoneally (treatment)1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Conversion of ergolines to hexahydro- and octahydrobenzo[f]quinolines (depyrroloergolines).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID62438In vitro inhibitory activity against dopamine receptor from calf caudate using [3H]spiperone as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID47773Compound was tested for percentage decrease in mean arterial blood pressure at 3 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID62173Inhibitory activity against Dopamine receptor D2 in calf corpus striatum using [3H]spiperone as radioligand1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID182949In vivo inhibitory activity against basal prolactin in male rat after subcutaneous administration1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID3480Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands.
AID196130Ability to induce contralateral rotational behavior in unilateral 6-hydroxydopamine nigrostriatal-lesioned rats and percent of rats turning was determined at intraperitoneal dosage of 0.1 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID189805Effect on homovanillic acid concentration in whole rat brain when 10 mg/kg was administered intraperitoneally1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
AID64917In vitro affinity at mutant D2 receptor (S194A) in C6 (glioma) cell membranes.2000Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16
CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors.
AID1154613Intrinsic activity at human dopamine D2L receptor expressed in CHO cells by [35S]GTPgammaS binding assay2014Journal of medicinal chemistry, Jul-10, Volume: 57, Issue:13
Novel aza-analogous ergoline derived scaffolds as potent serotonin 5-HT₆ and dopamine D₂ receptor ligands.
AID63227Affinity towards Dopamine receptor D21998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID48519Compound was tested for percentage increase in mean arterial blood pressure at 10 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID63040Affinity towards Dopamine receptor D11998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
AID185916Evaluation for contralateral turning in 6-hydroxy-dopamine-lesioned rats administered intraperitoneally at the dose 1 mg/kg Maximum intensity (turnings/min)1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents.
AID62729Dopaminergic activity assessed in vitro for displacement of [3H]apomorphine from specific binding sites on rat striatal membranes1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists.
AID47770Compound was tested for percentage decrease in mean arterial blood pressure at 10 mg/kg in anaesthetized cat (resting mean arterial pressure (mmHg))1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID65415Compound was tested for antagonistic activity against D2 receptor from rat striatum, used [3H]raclopride as radioligand1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Comparison of 5-HT1A and dopamine D2 pharmacophores. X-ray structures and affinities of conformationally constrained ligands.
AID48887Potency relative to apomorphine at 3 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID189800Effect on 3,4-Dihydroxyphenylacetic acid concentration in whole rat brain when 10 mg/Kg was administered intraperitoneally1989Journal of medicinal chemistry, Oct, Volume: 32, Issue:10
Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID48522Compound was tested for percentage increase in mean arterial blood pressure at 3 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID196865Ability to induce contralateral rotational behavior in unilateral 6-hydroxydopamine nigrostriatal-lesioned rats and no. of turns was determined after 15 minutes of start at intraperitoneal dosage of 0.1 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID182955In vivo inhibitory against lactation in female rat after peroral administration; hr = Not obtained1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID218775Inhibition of [3H]apomorphine binding to dopamine receptor of rat corpus striatum1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline.
AID65774Binding affinity towards Dopamine receptor D3 by displacement of [3H](+)-7-OH-DPAT.1997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID36797Alpha-2 adrenergic receptor activity assessed in vitro for displacement of [3H]clonidine from specific binding sites on rat striatal membranes1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Synthesis of 4-substituted 2H-naphth[1,2-b]-1,4-oxazines, a new class of dopamine agonists.
AID48358Sympathetic neuronal inhibiting activity in anaesthetized cat 3 at mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID203936In vitro inhibitory activity against serotonin receptor from whole rat brain using [3H]5-HT as radioligand1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphine.
AID188335Ability to lower the serum prolactin levels in comparison with that of pergolide was determined for the control rats at ip dose of 0.05 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID218779Inhibition of [3H]spiperone binding to dopamine receptor of rat corpus striatum1983Journal of medicinal chemistry, Aug, Volume: 26, Issue:8
Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline.
AID47764Compound was tested for percentage decrease in heart rate at 10 mg/kg in anaesthetized cat1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Proposed dopaminergic pharmacophore of lergotrile, pergolide, and related ergot alkaloid derivatives.
AID196866Ability to induce contralateral rotational behavior in unilateral 6-hydroxydopamine nigrostriatal-lesioned rats and no. of turns was determined after 15 minutes of start at intraperitoneal dosage of 1.0 mg/kg1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Synthesis of D-oxa tricyclic partial ergolines as dopamine agonists.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1345833Human D3 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346058Human alpha2B-adrenoceptor (Adrenoceptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345879Human D5 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345154Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
AID624210Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345788Human D2 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346159Human alpha2C-adrenoceptor (Adrenoceptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID624235Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346049Human alpha2A-adrenoceptor (Adrenoceptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345718Human D1 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1345879Human D5 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1345833Human D3 receptor (Dopamine receptors)1992European journal of pharmacology, Apr-10, Volume: 225, Issue:4
Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Aug-25, Volume: 268, Issue:24
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
AID1345718Human D1 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID624219Agonists at Human 5-Hydroxytryptamine receptor 5-HT2B2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345814Human D4 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (791)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990258 (32.62)18.7374
1990's161 (20.35)18.2507
2000's274 (34.64)29.6817
2010's77 (9.73)24.3611
2020's21 (2.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.82 (24.57)
Research Supply Index6.88 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index121.72 (26.88)
Search Engine Supply Index3.63 (0.95)

This Compound (41.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials123 (14.56%)5.53%
Reviews88 (10.41%)6.00%
Case Studies116 (13.73%)4.05%
Observational1 (0.12%)0.25%
Other517 (61.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Dopaminergic Modulation of Prefrontal Functions in Schizophrenic Patients: Adjuvant Therapy With Pergolide [NCT01066403]28 participants (Actual)Interventional2003-10-31Completed
Dose Response Trial of Pergolide for Cocaine Dependence [NCT00000248]Phase 30 participants Interventional1996-02-29Completed
Compassionate Use of Pergolide as Adjunctive Therapy to Levodopa/Carbidopa for Treating Parkinson's Disease [NCT00624741]0 participants Expanded AccessNo longer available
A Phase III, Double-blind, Placebo-controlled Randomised Trial to Determine the Efficacy and Safety of a Low (50 mg/Day) and High (100 mg/Day) Dose of Safinamide, as add-on Therapy, in Subjects With Early Idiopathic Parkinson's Disease Treated With a Stab [NCT00605683]Phase 3679 participants (Actual)Interventional2007-11-30Completed
Effective Adjunctive Use of Pergolide With Risperidone for Cognitive Impairment and Negative Symptoms in Schizophrenia [NCT00197483]20 participants Observational2003-03-31Suspended
The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder [NCT00252044]0 participants Interventional2000-10-31Recruiting
IV Cocaine Abuse: A Laboratory Model [NCT00000215]Phase 20 participants InterventionalCompleted
Pergolide Treatment for Substance Abusers [NCT00000269]Phase 20 participants Interventional1995-10-31Completed
[NCT00004433]74 participants Interventional1994-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]